Athlete's foot (also known as Tinea pedis) is a fungal infection usually caused by Trichophyton rubrum, T mentagrophytes, or Epidermophyton floccosum.1 Approximately 26.5 million individuals in the United States are afflicted with athlete's foot annually,2 and men tend to be affected more than women.
Athlete's foot generally occurs in 3 forms3:
Most mild cases of athlete's foot can be treated with the use of a nonprescription topical antifungal medication. In general, the majority of patients begin to see some form of improvement within 1 week of treatment. Even when improvement is shown, it is still recommended that treatment continue for 1 to 3 more weeks, depending on the type of athlete's foot.2
Various OTC topical antifungals are available in ointments, creams, sprays, and powders (Table). Pharmacists should encourage patients using these products to follow the recommendations listed by the manufacturers. Patients with diabetes always should seek the advice of their health care provider before trying to self-treat any foot problems. All patients should be encouraged to consult their health care provider if the use of topical nonprescription antifungals is not effective within the recommended time frame of treatment.
In severe cases, individuals should seek the attention of their health care provider for proper treatment. In many such cases, prescription topical and systemic antifungals may be necessary.
Recurrent infections may be a sign of another underlying medical problem and may need further medical evaluation.
Because athlete's foot tends to recur, prevention is the first step in avoiding recurrence.
Some precautionary measures can be suggested to patients to decrease the chances of developing an initial infection or a recurrence.
Ms. Terrie is a clinical pharmacy writer based in the northern Virginia area.
For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to: firstname.lastname@example.org.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs